Floatz logo

Vipoglanstat

Systemic Sclerosis

Gesynta Pharma ABSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Systemic Sclerosis cohort.

View all 41

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →